Skip to main content

Table 3 Results of network meta-analysis (data under the cells marked with italic drugs) and direct comparison (data above the cells marked with italic drugs) of all treatments

From: Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis

Placebo       − 0.05 (− 0.36, 0.27) [27, 29]   
0.14 (− 0.26, 0.54) Glyburide − 0.95 (− 1.29, − 0.61) [14, 32]    0.07 (− 0.11, 0.24) [31] 0.09 (− 0.19, 0.36) [33]   
1.09 (0.57, 1.62) 0.95 (0.61, 1.29) Gliclazide       
0.12 (− 0.72, 0.96) − 0.02 (− 0.76, 0.73) − 0.97 (− 1.79, − 0.15) Voglibose     − 0.20 (− 0.65, 0.25) [18]  
0.13 (− 0.50, 0.76) − 0.01 (− 0.50, 0.49) − 0.96 (− 1.56, − 0.36) 0.01 (− 0.85, 0.87) Metformin 0.05 (− 0.41, 0.52) [19]    
0.08 (− 0.35, 0.50) − 0.06 (− 0.23, 0.10) − 1.02 (− 1.40, − 0.64) − 0.05 (− 0.77, 0.68) − 0.05 (− 0.52, 0.41) Pioglitazone 0.06 (− 0.56, 0.68) [30]   − 0.06 (− 0.49, 0.38) [28]
0.05 (− 0.27, 0.36) − 0.10 (− 0.35, 0.16) − 1.05 (− 1.47, − 0.62) − 0.08 (− 0.86, 0.70) − − 0.09 (− 0.63, 0.46) − 0.03 (− 0.32, 0.26) Rosiglitazone   
0.32 (− 0.39, 1.03) 0.18 (− 0.41, 0.77) − 0.77 (− 1.46, − 0.09) 0.20 (− 0.25, 0.65) 0.19 (− 0.55, 0.92) 0.24 (− 0.33, 0.81) 0.27 (− 0.36, 0.91) Sitagliptin 0.18 (− 0.18, 0.55) [17]
0.14 (− 0.47, 0.74) − 0.01 (− 0.47, 0.46) − 0.96 (− 1.54, − 0.38) 0.01 (− 0.57, 0.59) 0.00 (− 0.63, 0.64) 0.06 (− 0.38, 0.49) 0.09 (− 0.43, 0.61) − 0.18 (− 0.55, 0.18) Conventional